Clinical trials: Hypertension, Pulmonary, open to volunteers
Pulmonary Disease, Pulmonary Hypertension
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
- Trial name
- NCT01730092
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Sleep Apnea, Obstructive Sleep Apnea
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
The investigators propose a prospective, observational study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension.
- Conditions
- Sleep Apnea, Obstructive Sleep Apnea, Pulmonary Hypertension, Epidemiology
- Trial name
- POSAPH (NCT05595200)
- Testing
- Level III portable sleep study
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Ventilator Pressure and Optimization of Compliance and Hemodynamics
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and…
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn
- Trial name
- VPOCH (NCT06512935)
- Testing
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Erythrocytosis, Pulmonary Hypertension
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Some people develop erythrocytosis, a condition characterized by having too many red blood cells, because of inherited changes (mutations) in genes such as EPAS1, EGLN1, or VHL.
- Conditions
- Erythrocytosis, Pulmonary Hypertension, Thrombosis
- Trial name
- NCT07895966
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery.
- Trial name
- H-FROG (NCT07847710)
- Testing
- Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 81 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated.
- Trial name
- AIPHY (NCT05566002)
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Pulmonary Hypertension (PH) Biorepository for Translational Research
Background: Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated.
- Trial name
- NCT07647549
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Congenital Peumonia, Persistent Pulmonary Hypertension of Newborn
Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates
The aim of the study 1. To evaluate safety and efficacy of melatonin as an adjuvant therapy to inhaled nitric oxide generated by NO generator in the treatment of pulmonary hypertension in full term neonates. 2.
- Conditions
- Congenital Peumonia, Persistent Pulmonary Hypertension of Newborn, Congenital Diaphragmatic Hernia
- Trial name
- NCT07850934
- Testing
- Melatonin, nitric oxide generator
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Ain Shams University
Pulmonary Arterial Hypertension
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea.
- Trial name
- Opsynvi RMP (NCT07890285)
- Volunteers
- 333 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain Crisis
Natural History of Sickle Cell Disease
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.
- Trial name
- NCT00081523
- Where
- 3 sites in United States
- Volunteers
- 3,500 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Pulmonary Hypertension Associated With HFpEF
Long-Term Open-Label Extension Study of Oral Levosimendan
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with…
- Trial name
- NCT07436689
- Testing
- TNX-103
- Where
- 10 sites in United States
- Volunteers
- 800 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
Spironolactone for Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high.
- Trial name
- NCT01712620
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)